John Chiminski

John Chiminski is an American engineer and business executive. Since 2009 he is the CEO of the pharmaceutical manufacturer Catalent. Under Chiminski's leadership Catalent became a publicly traded company in July 2014.[1] From 2007 to 2009, Chiminski was the President and CEO of General Electric Medical Diagnostics after serving in various engineering, operations and management roles in GE Healthcare for over 20 years.[2]

In June 2020, Chiminski announced[3] a deal to manufacture at least 100 million doses of Moderna COVID-19 vaccine. As of December 2020, Catalent has been producing daily about 500,0000 doses of the vaccine at its biologics facility in Bloomington, Indiana. [4]

Education

John Chiminski received a BS in Electrical Engineering from Michigan State University in 1986, an M.S. from Purdue University School of Electrical and Computer Engineering in 1987 an MBA from the Kellogg School of Management at Northwestern University in 1996.[5]

References
  1. "Catalent CEO: Leading advanced drug delivery". CNBC. July 31, 2014.
  2. "John Chiminski, Chair & Chief Executive Officer".
  3. "Moderna aims for light-speed COVID-19 shot rollout with Catalent fill-finish deal". Fierce Pharma.
  4. "Bloomington's Catalent Plays Key Role In Producing Moderna Vaccine". WTHR-TV. December 19, 2020.
  5. "John R. Chiminski, Distinguished Engineering Alumni 2012".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.